JUser: :_load: Unable to load user with ID: 291
JUser: :_load: Unable to load user with ID: 217

Monday, 30 June 2014 14:32

Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review

By  Christoforos Giannaki
Rate this item
(0 votes)

Restless legs syndrome (RLS) (or Willis–Ekbom disease) is a neurological disorder with high prevalence among the end-stage renal disease population. This is one of the most predominant types of secondary RLS, and it is called uremic RLS. Despite the fact that uremic RLS has been less studied compared to idiopathic RLS, recent studies now shed light in many aspects of the syndrome including clinical characteristics, impact, epidemiology, and treatment options. The current review discusses the above topics with special emphasis given on the management of uremic RLS, including the management of symptoms that often appear during a hemodialysis session. Uremic RLS symptoms may be ameliorated by using pharmacological and nonpharmacological treatments. Evidence so far shows that both approaches may be effective in terms of reducing the RLS symptom’s severity; nevertheless, more research is needed on the efficiency of treatments for uremic RLS.


Authors: Christoforos D Giannaki, Georgios M Hadjigeorgiou, Christina Karatzaferi, Marios C Pantzaris, Ioannis Stefanidis and Giorgos K Sakkas

Reference: Kidney Int 85: 1275-1282; advance online publication, October 9, 2013; doi:10.1038/ki.2013.394

Additional Info

  • Language: English
  • Contains Audio: No
  • Content Type: Articles
  • Source: KI
  • Year: 2013
  • Members Only: No
Read 1691 times Last modified on Monday, 16 January 2017 06:33

Global Operations Center

Avenue des Arts 1-2
1210 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact


Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact